$775 Million is the total value of Soleus Capital Management, L.P.'s 65 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 52.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRMD | Sell | IRADIMED CORP | $19,283,000 | -7.3% | 430,051 | -4.4% | 2.49% | +19.5% |
| ISEE | Sell | IVERIC BIO INC | $16,232,000 | -9.1% | 964,476 | -9.7% | 2.09% | +17.1% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $14,413,000 | -39.4% | 202,485 | -36.4% | 1.86% | -22.0% |
| FGEN | Sell | FIBROGEN INC | $12,794,000 | -41.5% | 1,064,356 | -31.4% | 1.65% | -24.6% |
| SNN | Sell | SMITH & NEPHEW PLCspdn adr new | $12,282,000 | -40.2% | 385,000 | -35.1% | 1.58% | -22.9% |
| STE | Sell | STERIS PLC | $9,975,000 | -21.3% | 41,260 | -20.8% | 1.29% | +1.3% |
| LNTH | Sell | LANTHEUS HLDGS INC | $9,869,000 | -80.6% | 178,427 | -89.9% | 1.27% | -75.1% |
| CVS | Sell | CVS HEALTH CORP | $9,362,000 | -34.2% | 92,500 | -33.0% | 1.21% | -15.2% |
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $7,476,000 | -73.2% | 112,696 | -76.5% | 0.96% | -65.5% |
| NTRA | Sell | NATERA INC | $6,305,000 | -70.3% | 155,000 | -31.9% | 0.81% | -61.8% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $5,802,000 | -51.0% | 189,797 | -49.9% | 0.75% | -36.8% |
| CCCC | Sell | C4 THERAPEUTICS INC | $4,045,000 | -77.6% | 166,736 | -70.3% | 0.52% | -71.1% |
| SIEN | Sell | SIENTRA INC | $3,644,000 | -47.5% | 1,641,337 | -13.2% | 0.47% | -32.4% |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $2,839,000 | -43.6% | 238,982 | -23.0% | 0.37% | -27.4% |
| CARA | Sell | CARA THERAPEUTICS INC | $1,934,000 | -62.8% | 159,200 | -62.7% | 0.25% | -52.0% |
| PCRX | Sell | PACIRA BIOSCIENCES INC | $1,698,000 | -72.2% | 22,250 | -78.1% | 0.22% | -64.2% |
| NVCR | Sell | NOVOCURE LTD | $1,431,000 | -14.4% | 17,275 | -22.4% | 0.18% | +10.8% |
| Sell | DA32 LIFE SCNCE TEC ACQSTN C | $972,000 | -71.7% | 100,000 | -71.4% | 0.12% | -63.7% | |
| LYRA | Exit | LYRA THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.00% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -13,000 | -100.0% | -0.02% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -2,850 | -100.0% | -0.02% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -10,250 | -100.0% | -0.06% | – |
| HOWL | Exit | WEREWOLF THERAPEUTICS INC | $0 | – | -64,585 | -100.0% | -0.08% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -11,000 | -100.0% | -0.09% | – |
| Exit | AVALO THERAPEUTICS INC | $0 | – | -770,000 | -100.0% | -0.13% | – | |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -158,700 | -100.0% | -0.25% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -68,320 | -100.0% | -0.25% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -175,152 | -100.0% | -0.28% | – |
| CUTR | Exit | CUTERA INC | $0 | – | -86,180 | -100.0% | -0.36% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -40,000 | -100.0% | -0.37% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -27,500 | -100.0% | -0.37% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -338,760 | -100.0% | -0.40% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -51,000 | -100.0% | -0.44% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -298,700 | -100.0% | -0.49% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -98,800 | -100.0% | -0.54% | – |
| BVS | Exit | BIOVENTUS INC | $0 | – | -428,397 | -100.0% | -0.62% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -508,500 | -100.0% | -11.32% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -1,292,000 | -100.0% | -14.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.